ALS drugs from Denali, Calico come up short, marking more failures for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More
Nvidia stock rises after the artificial-intelligence chip maker unveils its next generation gaming graphic cards, while ...
BioSpace4h
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Denali Water Solutions says stink in River Valley caused no ‘physical harm’
Fort Smith area plaintiffs have not shown they suffered physical harm from an intermittent but widespread offensive smell in ...
On screen: Wampanoag character makes first appearance on PBS' national 'Molly of Denali'
Mashpee Wampanoag educator Kitty Hendricks-Miller (Nanaweetah), consults on PBS 'Molly of Denali' as Cape-based tribe debuts ...
Denali Therapeutics’ Phase II/III trial of ALS therapy fails to meet primary endpoint
The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
clinicaltrialsarena1h
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial
Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.
Investor's Business Daily on MSN1h
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a ...
Denali Therapeutics' ALS drug fails in mid-to-late stage trial
Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...
Denali Therapeutics Says ALS Trial Didn't Meet Endpoints
Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.
Alaska Dispatch News1dOpinion
Opinion: We don’t need a vote to know Alaskans have long preferred Denali over McKinley
The state of Alaska and Alaskans themselves have always had a clear record that they prefer to call North America’s tallest ...
Taiwan News19h
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...